Detect and treat cervical pre-cancer before it becomes cancer.
GCRF funds research, contributes resources, and trains clinicians to screen and treat gynecologic cancers, with a focus on women who have never been screened for cervical cancer.
100+
DIFFERENT TYPES OF HUMAN PAPILLOMA VIRUS
13 are cancer causing, known as the high risk type. Human Papilloma Virus (HPV) types 16 and 18 cause 70% of cervical cancers and precancerous cervical lesions. HPV can also cause cancers of the anus, vulva, vagina, penis, throat and tongue.
350,000
CASES OCCUR ANNUALLY AROUND THE WORLD
More than 270,000 women die from cervical cancer annually. It is the second most common cancer in women living in less developed regions and more than 85% of cervical cancer deaths occur in low and middle-income countries.
1/60
WOMEN WILL BE AFFECTED BY LICHEN SCLEROSUS
4-7% of women with lichen sclerosus will develop vulvar cancer unless treated. Only optimal treatment of lichen sclerosus with ultra-high potency corticosteroids has been shown to lower the risk of developing vulvar cancer.
Our mission is to fund research, contribute resources, and provide training for the screening and treatment of gynecologic cancers.
Our Research
-
Cervical Screening by Pap Test and Visual Inspection Enabling Same-Day Biopsy in Low-Resource, High-Risk Communities
Obstetrics and Gynecology
-
Designing Low-Cost, Accurate Cervical Screening Strategies That Take Into Account COVID-19: A Role for Self-Sampled HPV Typing
Infectious Agents and Cancer
-
Prospective Cohort Study Examining Cervical Cancer Screening Methods in HIV-positive and HIV-negative Cambodian Women
BMJ Open
Our Partners
U.S. National Cancer Institute
McCormick Center · GWU
Rays of Hope Jinja · Uganda
National Center for HIV/AIDS, Dermatology and STD · Cambodia
Public Health Research Institute of India
Sihanouk Hospital · Cambodia
Amazon Promise · Peru
Mysore Consortium Against Cervical Cancer
The United Foundation for China's Health
Uganda Cancer Institute
Liger Medical
Our Goals
Focus on Prevention
The GCRF is focused on the development of cost-effective strategies based on new technologies to screen for cervical pre-cancers. There are hundreds of millions of women in resource poor countries who have never been screened. The goal is to detect and treat pre-cancerous conditions before they develop into cervical cancer.
Focus on Treatment
The GCRF is focused on developing efficacious, cost-effective, and safe long-term treatment strategies for both cervical and vulvar pre-cancerous conditions.
Focus on Research
The GCRF is currently partnering with the US National Cancer Institute (NCI) in its “Accelerated Control of Cervical Cancer" moonshot program which will use a combination of PCR HPV testing, advanced digital optics, and artificial intelligence to determine the optimal cervical cancer treatment algorithm for low resource countries. Additionally, the GCRF is partnering with the McCormick Genomic and Proteomic Center at George Washington University to determine the biologic pathways that lead to vulvar cancer.
Focus on Collaboration
In addition to its research collaborations, the GCRF team actively collaborates with other non-profit organizations to provide gynecologic cancer care in resource poor regions. We have worked with Amazon Promise (Peru), Sihanouk Hospital Center of Hope (Cambodia), Takeo Regional Hospital (Cambodia), NCHADS - The National Center for HIV/AIDS (Cambodia), Cure Cervical Cancer (Kenya), United Foundation for China’s Health (China), and Rays of Hope Jinja (Uganda).
Our strategy is to fund research and develop partnerships with government agencies, NGOs and foundations to implement our research and to develop gynecologic cancer screening programs
One visit. Portable devices. One life changed.
Step 1: Self-Sampling
A woman collects her own HPV swab. No pelvic exam. No stigma. No specialist required.
Step 2: Rapid HPV Testing
On site ScreenFire identifies HPV type within minutes, flagging the highest risk patients.
Step 3: AI-powered Evaluation
IRIS colposcope captures a cervical image. AI reads it instantly. High-risk women receive same-day treatment.